October 24, 2018

TO: NOTICE TO ALL MANITOBA PHARMACISTS AND PHYSICIANS

RE: Removal of lisdexamfetamine (Vyvanse®), methylphenidate OROS (Concerta®), and methylphenidate MLR (Biphentin®) from the M3P Program

Following extensive review of the literature, an environmental scan of the prescription monitoring practices of other provinces, and pharmacist responses to a call for feedback, the Councils of the College of Pharmacists of Manitoba (CPhM) and the College of Physicians and Surgeons of Manitoba (CPSM) have approved that, effective immediately, the following three long-acting stimulants used to treat attention deficit/hyperactivity disorder are removed from the list of drugs covered by the M3P Program:

1. lisdexamfetamine (Vyvanse®)
2. methylphenidate OROS (Concerta®)
3. methylphenidate MLR (Biphentin®)

All other stimulants, including mixed amphetamine salts (Adderall XR®), remain on the M3P drug list. An updated M3P drug list can be found here.

Please note that verbal orders of these medications are not permitted, but electronic and fax transmission of these prescriptions are acceptable.

For questions or further information, pharmacists can contact the CPhM at 204-233-1411 and physicians can contact the CPSM at 204-774-4344.

Regards,

Ms. Susan Lessard-Friesen
Registrar
College of Pharmacists of Manitoba

Dr. Anna Ziomek, MD
Registrar
College of Physicians & Surgeons of Manitoba